Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532680 | 1.00 | MEN1 (0.53) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL5523736 | 0.84 | L3MBTL1 (0.59) | MEN1KMT2ANPC1ALDH1A1KDM4E | |
| SCHEMBL5523733 | 0.84 | L3MBTL1 (0.59) | MEN1KMT2ANPC1ALDH1A1KDM4E | |
| SCHEMBL664380 | 0.83 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL11457462 | 0.82 | TAS2R14 (0.53) | MEN1KMT2AGAASMN1; SMN2OPRM1 | |
| SCHEMBL622656 | 0.80 | IDO1 (0.50) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8191635 | 0.79 | FABP7 (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL8502974 | 0.79 | FABP7 (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6988354 | 0.78 | KDM4E (0.74) | MEN1KMT2AGAANPC1RAB9A | |
| Ammonia Solution, Strong SCHEMBL8172708 | 0.78 | IDO1 (0.48) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | MEN1 3887/4885KMT2A 1221/4885GAA 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.